Abiraterone
The serum concentration of Oxaliplatin can be increased when it is combined with Abiraterone.
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Oxaliplatin.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Oxaliplatin.
Advertisement
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Oxaliplatin.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Anthrax immune globulin human.
Apalutamide
The serum concentration of Oxaliplatin can be decreased when it is combined with Apalutamide.
Advertisement
Azithromycin
The metabolism of Oxaliplatin can be decreased when combined with Azithromycin.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Oxaliplatin.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Bacillus calmette-guerin substrain connaught live antigen.
Advertisement
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Bacillus calmette-guerin substrain tice live antigen.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Oxaliplatin.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Oxaliplatin.
Bortezomib
The metabolism of Oxaliplatin can be decreased when combined with Bortezomib.
Bupropion
The serum concentration of Oxaliplatin can be increased when it is combined with Bupropion.
Cabazitaxel
Oxaliplatin may increase the myelosuppressive activities of Cabazitaxel.
Caffeine
The metabolism of Oxaliplatin can be decreased when combined with Caffeine.
Citalopram
The metabolism of Oxaliplatin can be decreased when combined with Citalopram.
Clotrimazole
The metabolism of Oxaliplatin can be decreased when combined with Clotrimazole.
Clozapine
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Clozapine.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Oxaliplatin.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Oxaliplatin.
Cyproterone Acetate
The serum concentration of Oxaliplatin can be decreased when it is combined with Cyproterone acetate.
Deferasirox
The serum concentration of Oxaliplatin can be increased when it is combined with Deferasirox.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Oxaliplatin.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Oxaliplatin.
Deutetrabenazine
Oxaliplatin may increase the QTc-prolonging activities of Deutetrabenazine.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Oxaliplatin.
Digoxin
Digoxin may decrease the cardiotoxic activities of Oxaliplatin.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Oxaliplatin.
Docetaxel
Oxaliplatin may increase the myelosuppressive activities of Docetaxel.
DOCETAXEL ANHYDROUS
Oxaliplatin may increase the myelosuppressive activities of Docetaxel.
Dothiepin
The metabolism of Oxaliplatin can be decreased when combined with Dosulepin.
Eltrombopag
The serum concentration of Oxaliplatin can be increased when it is combined with Eltrombopag.
Fingolimod
Oxaliplatin may increase the immunosuppressive activities of Fingolimod.
Fluvoxamine
The metabolism of Oxaliplatin can be decreased when combined with Fluvoxamine.
Fosphenytoin
The serum concentration of Fosphenytoin can be decreased when it is combined with Oxaliplatin.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hepatitis B Vaccine (Recombinant).
Isavuconazole
The serum concentration of Oxaliplatin can be increased when it is combined with Isavuconazole.
Isoniazid
The metabolism of Oxaliplatin can be decreased when combined with Isoniazid.
Leflunomide
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Leflunomide.
Lidocaine
The metabolism of Oxaliplatin can be decreased when combined with Lidocaine.
Macimorelin
Oxaliplatin may increase the QTc-prolonging activities of Macimorelin.
Mexiletine
The metabolism of Oxaliplatin can be decreased when combined with Mexiletine.
Midostaurin
The metabolism of Oxaliplatin can be decreased when combined with Midostaurin.
Natalizumab
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Natalizumab.
Nevirapine
The metabolism of Oxaliplatin can be decreased when combined with Nevirapine.
Nicotine
The metabolism of Oxaliplatin can be decreased when combined with Nicotine.
Nicotine Polacrilex
The metabolism of Oxaliplatin can be decreased when combined with Nicotine.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Oxaliplatin.
Osimertinib
The serum concentration of Oxaliplatin can be decreased when it is combined with Osimertinib.
Ouabain
Ouabain may decrease the cardiotoxic activities of Oxaliplatin.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Oxaliplatin.
Paclitaxel
Oxaliplatin may increase the myelosuppressive activities of Paclitaxel.
Peginterferon Alfa-2b
The serum concentration of Oxaliplatin can be increased when it is combined with Peginterferon alfa-2b.
Phenytoin
The serum concentration of Phenytoin can be decreased when it is combined with Oxaliplatin.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxaliplatin.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Oxaliplatin.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Oxaliplatin.
Ribociclib
The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Oxaliplatin.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Oxaliplatin.
Rolapitant
The serum concentration of Oxaliplatin can be increased when it is combined with Rolapitant.
Ropinirole
The metabolism of Oxaliplatin can be decreased when combined with Ropinirole.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Rubella virus vaccine.
Rucaparib
The metabolism of Oxaliplatin can be decreased when combined with Rucaparib.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Salmonella typhi ty21a live antigen.
Simeprevir
The metabolism of Oxaliplatin can be decreased when combined with Simeprevir.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Oxaliplatin.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Oxaliplatin.
Tenofovir Disoproxil
The metabolism of Oxaliplatin can be decreased when combined with Tenofovir disoproxil.
Teriflunomide
The serum concentration of Oxaliplatin can be decreased when it is combined with Teriflunomide.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Theophylline
The metabolism of Oxaliplatin can be decreased when combined with Theophylline.
Theophylline anhydrous
The metabolism of Oxaliplatin can be decreased when combined with Theophylline.
Ticlopidine
The metabolism of Oxaliplatin can be decreased when combined with Ticlopidine.
Tipiracil
The serum concentration of Tipiracil can be increased when it is combined with Oxaliplatin.
Tofacitinib
Oxaliplatin may increase the immunosuppressive activities of Tofacitinib.
Topotecan
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Topotecan.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Oxaliplatin.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Varicella Zoster Vaccine (Live/Attenuated).
Vemurafenib
The serum concentration of Oxaliplatin can be increased when it is combined with Vemurafenib.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Yellow Fever Vaccine.
